GPR35 and ulcerative colitis: The reduction of permeability in colonoids from hGPR35a-HA mice by treatment with lodoxamide suggests that activators of GPR35 might be useful in the treatment of lower gut inflammatory conditions, such as ulcerative colitis, in which mucosal barrier function is compromised.